TY - JOUR
KW - Buprenorphine/therapeutic use
KW - COVID-19
KW - Humans
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/drug therapy
KW - Pandemics
KW - SARS-CoV-2
KW - Telemedicine
AU - D. T. Moore
AU - D. L. Wischik
AU - C. M. Lazar
AU - G. G. Vassallo
AU - M. I. Rosen
A1 - 
AD - VA Connecticut Healthcare System, West Haven, CT, USA; Yale University, School of Medicine, Department of Psychiatry, New Haven, CT, USA. Electronic address: David.Moore2cdbc8@va.gov.; VA Connecticut Healthcare System, West Haven, CT, USA; Yale University, School of Nursing, Orange, CT, USA.; VA Connecticut Healthcare System, West Haven, CT, USA; Yale University, School of Medicine, Department of Psychiatry, New Haven, CT, USA.; VA Connecticut Healthcare System, West Haven, CT, USA; Yale University, School of Medicine, Department of Psychiatry, New Haven, CT, USA.; VA Connecticut Healthcare System, West Haven, CT, USA; Yale University, School of Medicine, Department of Psychiatry, New Haven, CT, USA.
BT - Preventive medicine
C5 - Education & Workforce; HIT & Telehealth; Opioids & Substance Use
CP - Pt 2
CY - United States
DO - 10.1016/j.ypmed.2021.106603
IS - Pt 2
JF - Preventive medicine
LA - eng
M1 - Journal Article
PB - . Published by Elsevier Inc
PP - United States
PY - 2021
SN - 1096-0260; 0091-7435
SP - 106603
T1 - The intertwined expansion of telehealth and buprenorphine access from a prescriber hub
T2 - Preventive medicine
TI - The intertwined expansion of telehealth and buprenorphine access from a prescriber hub
U1 - Education & Workforce; HIT & Telehealth; Opioids & Substance Use
U2 - 33974959
U3 - 10.1016/j.ypmed.2021.106603
VL - 152
VO - 1096-0260; 0091-7435
Y1 - 2021
Y2 - Nov
ER -